{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-26-007081","form_type":"8-K","ticker":"AVIR","cik":"0001593899","company_name":"Atea Pharmaceuticals, Inc.","filed_at":"2026-01-08T23:59:59+00:00","discovered_at":"2026-05-14T18:02:35.580618+00:00","generated_at":"2026-05-16T11:12:39.816452+00:00","sec_items":["2.02","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.55,"calibrated_materiality_score":0.55,"confidence":"high","headline":"Atea ends 2025 with $301.8M cash; Phase 3 HCV data due mid-2026; HEV program advancing","bullets":["Cash and investments $301.8M at Dec 31, 2025; cash runway expected through 2027.","Phase 3 HCV C-BEYOND topline results mid-2026; C-FORWARD results year-end 2026.","HEV Phase 1 study for AT-587 planned mid-2026; preclinical shows potent nanomolar anti-HEV activity.","Market survey of 153 top DAA prescribers supports need for new HCV regimen; global HCV market ~$3B net sales annually.","Atea will evaluate strategic transactions and global commercialization options to maximize reach."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-26-007081","json":"https://secwatch.observer/filing/0001193125-26-007081.json","markdown":"https://secwatch.observer/filing/0001193125-26-007081.md","text":"https://secwatch.observer/filing/0001193125-26-007081.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1593899/000119312526007081/0001193125-26-007081-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1593899/000119312526007081/d800383d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-16T11:12:39.816452+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}